Compass is still being developed and is effectively in beta. Some content and features may be incomplete, change, or not work as expected.

Content is anchored to trusted sources where available, but Compass has not yet been clinically reviewed. It provides general information rather than medical advice.

Feedback helps us identify gaps, errors, usability problems and opportunities to improve Compass over time.

How Compass is developedGive feedback

ALS Untangled does not endorse caffeine as an ALS treatment

Original source

CaffeineALSUntangled · 16 June 2023 (opens in a new tab)

ALS Untangled reviewed caffeine as a possible treatment for amyotrophic lateral sclerosis (ALS). It found contradictory results in preclinical models and no clear relationship between caffeine intake and disease progression in two cohort studies. The review does not endorse caffeine as an ALS treatment.

Why this matters

People with ALS should not interpret the available evidence as showing that caffeine slows disease progression. The review says caffeine is inexpensive and reasonably safe at doses below 400 mg daily, but this does not establish a treatment benefit. [S1]

Limitations and context

This is an independent expert review, not a new clinical trial. The evidence it assessed includes contradictory preclinical findings and two cohort studies, which found no clear relationship between caffeine intake and ALS progression. The review does not establish whether caffeine benefits people with ALS or changes treatment decisions. [S1]

Summarised by Compass 9 August 2026

This summary was generated by AI from the source listed above. It is not medical advice, so read the original source for anything that affects your care.

Relevant to you?